CoChat
Sign Up
Cited by 257

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Strategic design of extracellular vesicle drug delivery systems

Armstrong, James P.K., Stevens, Molly M.·2018·Advanced Drug Delivery Reviews
DOI 10.1016/j.addr.2018.06.017PMC PMC6606438
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2018.06.017

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Théry, 2002, Exosomes: composition, biogenesis and function, Nat. Rev. Immunol., 2, 569, 10.1038/nri855 · DOI
  2. Skog, 2008, Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nat. Cell Biol., 10, 1470, 10.1038/ncb1800 · DOI · Paper page
  3. Buzas, 2014, Emerging role of extracellular vesicles in inflammatory diseases, Nat. Rev. Rheumatol., 10, 356, 10.1038/nrrheum.2014.19 · DOI
  4. Malda, 2016, Extracellular vesicles - new tool for joint repair and regeneration, Nat. Rev. Rheumatol., 12, 243, 10.1038/nrrheum.2015.170 · DOI
  5. El Andaloussi, 2013, Extracellular vesicles: biology and emerging therapeutic opportunities, Nat. Rev. Drug Discov., 12, 347, 10.1038/nrd3978 · DOI · Paper page
  6. Fuhrmann, 2015, Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges, Nano Today, 10, 397, 10.1016/j.nantod.2015.04.004 · DOI
  7. Sun, 2010, A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes, Mol. Ther., 18, 1606, 10.1038/mt.2010.105 · DOI
  8. Zhuang, 2011, Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain, Mol. Ther., 19, 1769, 10.1038/mt.2011.164 · DOI · Paper page
  9. El-Andaloussi, 2012, Exosome-mediated delivery of siRNA in vitro and in vivo, Nat. Protoc., 7, 2112, 10.1038/nprot.2012.131 · DOI
  10. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  11. Silva, 2013, Magnetic and photoresponsive theranosomes: translating cell-released vesicles into smart nanovectors for cancer therapy, ACS Nano, 7, 4954, 10.1021/nn400269x · DOI
  12. Armstrong, 2017, Re-engineering extracellular vesicles as smart nanoscale therapeutics, ACS Nano, 11, 69, 10.1021/acsnano.6b07607 · DOI
  13. Fuhrmann, 2015, Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins, J. Control. Release, 205, 35, 10.1016/j.jconrel.2014.11.029 · DOI
  14. Fuhrmann, 2018, Engineering extracellular vesicles with the tools of enzyme prodrug therapy, Adv. Mater.
  15. Ohno, 2013, Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells, Mol. Ther., 21, 185, 10.1038/mt.2012.180 · DOI · Paper page
  16. Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 · DOI
  17. Kim, 2016, Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells, Nanomed. Nanotechnol., 12, 655, 10.1016/j.nano.2015.10.012 · DOI · Paper page
  18. Li, 2017, Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model, Hepatology, 65, 501, 10.1002/hep.28735 · DOI
  19. Xin, 2013, MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles, Stem Cells, 31, 2737, 10.1002/stem.1409 · DOI
  20. Cooper, 2014, Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice, Mov. Disord., 29, 1476, 10.1002/mds.25978 · DOI
  21. Haney, 2015, Exosomes as drug delivery vehicles for Parkinson's disease therapy, J. Control. Release, 207, 18, 10.1016/j.jconrel.2015.03.033 · DOI · Paper page
  22. Ingato, 2016, Good things come in small packages: overcoming challenges to harness extracellular vesicles for therapeutic delivery, J. Control. Release, 241, 174, 10.1016/j.jconrel.2016.09.016 · DOI
  23. Yoo, 2011, Bio-inspired, bioengineered and biomimetic drug delivery carriers, Nat. Rev. Drug Discov., 10, 521, 10.1038/nrd3499 · DOI
  24. Rak, 2012, Extracellular vesicles - vehicles that spread cancer genes, Bioessays, 34, 489, 10.1002/bies.201100169 · DOI
  25. Pegtel, 2010, Functional delivery of viral miRNAs via exosomes, Proc. Natl. Acad. Sci. U. S. A., 107, 6328, 10.1073/pnas.0914843107 · DOI
  26. Fevrier, 2004, Cells release prions in association with exosomes, Proc. Natl. Acad. Sci. U. S. A., 101, 9683, 10.1073/pnas.0308413101 · DOI
  27. Webber, 2013, How pure are your vesicles?, J. Extracell. Vesicles, 2, 10.3402/jev.v2i0.19861 · DOI · Paper page
  28. Corso, 2017, Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography, Sci. Rep., 7, 10.1038/s41598-017-10646-x · DOI
  29. Lener, 2015, Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper, J. Extracell. Vesicles, 4, 10.3402/jev.v4.30087 · DOI · Paper page
  30. Clayton, 2003, Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59, Eur. J. Immunol., 33, 522, 10.1002/immu.200310028 · DOI
  31. Bae, 2011, Targeted drug delivery to tumors: myths, reality and possibility, J. Control. Release, 153, 198, 10.1016/j.jconrel.2011.06.001 · DOI
  32. Headland, 2015, Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis, Sci. Transl. Med., 7, 190, 10.1126/scitranslmed.aac5608 · DOI
  33. Wood, 2011, Exosomes and the blood-brain barrier: implications for neurological diseases, Ther. Deliv., 2, 1095, 10.4155/tde.11.83 · DOI
  34. Tominaga, 2015, Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier, Nat. Commun., 6, 6716, 10.1038/ncomms7716 · DOI · Paper page
  35. Lösche, 2004, Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils, Platelets, 15, 109, 10.1080/09537100310001649885 · DOI
  36. Smyth, 2015, Biodistribution and delivery efficiency of unmodified tumor-derived exosomes, J. Control. Release, 199, 145, 10.1016/j.jconrel.2014.12.013 · DOI
  37. Van der Meel, 2014, Extracellular vesicles as drug delivery systems: lessons from the liposome field, J. Control. Release, 195, 72, 10.1016/j.jconrel.2014.07.049 · DOI
  38. Zomer, 2015, In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behaviour, Cell, 161, 1046, 10.1016/j.cell.2015.04.042 · DOI
  39. Zhang, 2008, Nanoparticles in medicine: therapeutic applications and developments, Clin. Pharmacol. Ther., 83, 761, 10.1038/sj.clpt.6100400 · DOI
  40. Urquhart, 1997, Can drug delivery systems deliver value in the new pharmaceutical marketplace?, Br. J. Clin. Pharmacol., 44, 413, 10.1046/j.1365-2125.1997.t01-1-00610.x · DOI
  41. Patil, 2014, Novel methods for liposome preparation, Chem. Phys. Lipids, 177, 8, 10.1016/j.chemphyslip.2013.10.011 · DOI
  42. Armstrong, 2016, Strategies for cell membrane functionalization, Exp. Biol. Med., 241, 1098, 10.1177/1535370216650291 · DOI
  43. Ulrich, 2002, Biophysical aspects of using liposomes as delivery vehicles, Biosci. Rep., 22, 129, 10.1023/A:1020178304031 · DOI
  44. Menger, 1998, Chemistry and physics of giant vesicles as biomembrane models, Curr. Opin. Chem. Biol., 2, 726, 10.1016/S1367-5931(98)80110-5 · DOI
  45. Barenholz, 2001, Liposome application: problems and prospects, Curr. Opin. Colloid Interface Sci., 6, 66, 10.1016/S1359-0294(00)00090-X · DOI · Paper page
  46. Takahashi, 2013, Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection, J. Biotechnol., 165, 77, 10.1016/j.jbiotec.2013.03.013 · DOI
  47. Lai, 2014, Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter, ACS Nano, 8, 483, 10.1021/nn404945r · DOI
  48. Morishita, 2015, Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice, J. Pharm. Sci., 104, 705, 10.1002/jps.24251 · DOI
  49. Kooijmans, 2016, PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time, J. Control. Release, 224, 77, 10.1016/j.jconrel.2016.01.009 · DOI
  50. Lopez-Berestein, 1984, Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer, Cancer Res., 375
  51. Conley, 1993, Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin, Cancer Chemother. Pharmacol., 33, 107, 10.1007/BF00685327 · DOI
  52. Sengupta, 2000, Etopside encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies, Pharmacol. Res., 42, 459, 10.1006/phrs.2000.0714 · DOI
  53. Gabizon, 1994, Clinical studies of liposome-encapsulated doxorubicin, Acta Oncol., 33, 779, 10.3109/02841869409083948 · DOI
  54. Morse, 2005, A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer, J. Transl. Med., 3, 9, 10.1186/1479-5876-3-9 · DOI
  55. Escudier, 2005, Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial, J. Transl. Med., 3, 10, 10.1186/1479-5876-3-10 · DOI
  56. Besse, 2016, Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC, Oncoimmunology, 5, 10.1080/2162402X.2015.1071008 · DOI · Paper page
  57. Kordelas, 2014, MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease, Leukemia, 28, 970, 10.1038/leu.2014.41 · DOI
  58. Dai, 2008, Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer, Mol. Ther., 16, 782, 10.1038/mt.2008.1 · DOI

Cited by

Sorted by citations

See all 257

Metadata

Authors
Armstrong, J. P. K., & Stevens, M. M.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2018-05
Volume
130
Pages
12-16
ISSN
0169-409X
DOI
10.1016/j.addr.2018.06.017
PMC
PMC6606438
Cited by
257
References
8
Language
en
Licence
Funders
  • Arthritis Research U.K. Foundation (21138)
  • UK Regenerative Medicine (MR/K026682/1)
  • MRC (MR/L012677/1)
  • ERC Seventh Framework Programme (616417)
  • Wellcome Trust (098411/Z/12/Z)
  • GlaxoSmithKline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review